William S. Blaner, PhD

Overview

Most of our recent work has employed genetic manipulations of mice to study these processes. One research project is focused on the essential biological processes that are mediated by retinol-binding protein (RBP), the sole serum transport protein for retinol. We have disrupted the gene for RBP in mice and demonstrated that these mice are a useful model to study retinoid-dependent actions, including ones in cancer prevention and normal embryologic development. The retinoid status of these mice is exceeding tenuous and consequently retinoid-dependent functions can be conveniently studied in this animal model. The laboratory is also studying the processes through which provitamin A carotenoids like β-carotene are converted to retinoids. Carotenoid conversion to retinoids is accomplished by the combined actions of three enzymes and several other intestinal proteins and we are studying how these different proteins interact and are regulated to ensure efficient conversion of carotenoids to retinoids. Another project in the laboratory explores the molecular basis for why 13-cis-retinoic acid (Accutane) is a more effective drug than all-trans-retinoic acid (Tretinoin) even though the latter retinoid is more active in regulating retinoid-responsive genes. Here we are seeking to establish actions for retinoids that are independent of their roles as transcriptional regulators. Finally the laboratory is developing new methodologies for assessing retinoid status in populations of infants that are at risk of vitamin A deficiency. This collaborative work that involves investigators in Brazil seeks to establish practical and cost-effective new methods for use assessing vitamin A status in field settings.

Credentials & Experience

Honors & Awards

1991 Ruth L. Pike Lecture and Award, Distinguished Young Investigator, Pennsylvania State University 1997 Member, U.S. Department of Agriculture Improving Human Nutrition for Optimal Health Review Panel, (April 1994, March 1995, March 1997) 1997 Organizing Committee Member, 1997 European Retinoid Research Group Meeting, Nice, France 1998 Committee Member, Food and Drug Administration, Food Safety Committee, Thirty Month Review of the Safety of Olestra 1999 Advisory Committee Member, National Cancer Institute, Consensus Panel Reviewing the Clinical Applications of 4-Hydroxyphenylretinamide 1999 Advisory Committee Member, Society of Investigative Dermatology, Consensus Panel Reviewing the Safety and Clinical Application of Isotretinoin 2000 Peer Review Team for the 5-Year External Evaluation of the Department of Nutritional Sciences, Texas A&M University, College Station, TX

Research

Retinoid (vitamin A and its metabolites) metabolism and actions.